GoodRx (NASDAQ:GDRX) jumped 18% after revealing a partnership with Novo Nordisk (NYSE:NVO) to offer Ozempic and Wegovy to eligible self-paying patients at a monthly price of $499. This agreement represents a notable price cut for these widely used GLP-1 medications and marks the first time Ozempic is available at this self-pay rate.

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street Journal, the consensus rating on Goodrx Holdings currently sits at “overweight” with price targets going as high as $7.0, indicating potential “upside” of another 35% from here.